As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.
|Articles|July 11, 2005
Letters to the editor
AstraZeneca was encouraged by the article "Compounding Pharmacies Come Under Attack" (April 18), as it highlights potential dangers associated with pharmacy-manufactured medications, including the lack of assurance to patients and physicians that these drugs are safe and effective. We commend Drug Topics for highlighting this growing issue.
Advertisement
Advertisement
Related to this article
Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
Pennsylvania has become the center of the outbreak as cases exceed 775 alongside conflicting mortality reports.
The LATA trial found long-acting cabotegravir–rilpivirine is better than daily oral therapy at keeping adolescents virologically suppressed.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
Mark Garofoli, PharmD, BCGP, CPE, CTTS, explains how to guide patients past crowded combination products, uncertain decongestants, and hidden risks in OTC aisles.
Chad Worz, PharmD, BCGP, FASCP, explains why the Main Street Pharmacy Access Act's reimbursement provisions are key to unlocking pharmacy's clinical future.
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Approves Update for Winrevair Based on Phase 3 HYPERION Trial Data
2
Conflicting Measles Reports Perpetuate as Cases Continue to Rise
3
Injectable HIV Treatment Beats Daily Pills in Adolescent Trial
4
PPV23 Vaccination Found to Not Reduce Cardiovascular Risk
5